Last reviewed 2026-04-22 · How we verify

Recombinant Streptokinase

Recombinant streptokinase is a fibrinolytic enzyme that activates plasminogen to plasmin, dissolving blood clots by breaking down fibrin.

Recombinant streptokinase is a fibrinolytic enzyme that activates plasminogen to plasmin, dissolving blood clots by breaking down fibrin. Used for Acute myocardial infarction, Acute ischemic stroke, Pulmonary embolism.

At a glance

Mechanism of action

Streptokinase is a serine protease produced by Streptococcus bacteria that binds to plasminogen and converts it to its active form, plasmin. Plasmin then degrades fibrin, the main structural component of blood clots, leading to thrombolysis. This mechanism makes it effective for treating acute thrombotic events where rapid clot dissolution is needed.

Approved indications

• Acute myocardial infarction
• Acute ischemic stroke
• Pulmonary embolism
• Deep vein thrombosis

Common side effects

• Bleeding
• Allergic reaction
• Hypotension
• Arrhythmia
• Fever

Key clinical trials

• Effect of Thrombolysis on 30-day Mortality in Intermediate High Risk Pulmonary Patients With Low Bleeding Risk (NA)
• A Trial Using Double-Bolus THR-100 Versus Streptokinase (PHASE3)
• Recombinant Streptokinase Versus Urokinase in Pulmonary Embolism in China (RESUPEC) (PHASE4)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

• Recombinant Streptokinase CI brief — competitive landscape report
• Recombinant Streptokinase updates RSS · CI watch RSS
• Beijing Chao Yang Hospital portfolio CI